Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Nektar/Bayer Agree To Develop Inhaled Amikacin For Hospital-Acquired Pneumonia

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Product combining Nektar’s deep-lung delivery technology and amikacin formulation could reach market in 2010-2011 timeframe, Nektar COO tells “The Pink Sheet” DAILY.

You may also be interested in...



Nektar Quiets Partnering Talk, Will Keep Oncology Drug For Itself

Auspicious data from a pair of Phase II studies has prompted the company to cease partnership discussions - and reassess its priorities.

Nektar Quiets Partnering Talk, Will Keep Oncology Drug For Itself

Auspicious data from a pair of Phase II studies has prompted the company to cease partnership discussions - and reassess its priorities.

Nektar Starts Major Push In Opioid-Induced Constipation Space

Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent ‘March-In’ Policy Shift Will Likely Drive Uncertainty More Than Price Drops

Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions

US FDA, NCI Collaboration Deepens To Include Clinical Trial Innovation ‘Think Tank’

All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science

See All
UsernamePublicRestriction

Register

PS066549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By